Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Dow Jones

IBM Shares Slide Despite Strong Earnings as Software Unit Underperforms

Robert Sasse by Robert Sasse
August 30, 2025
in Dow Jones, Earnings, Tech & Software
0
IBM Stock
0
SHARES
243
VIEWS
Share on FacebookShare on Twitter

IBM delivered a textbook example of a “buy the rumor, sell the news” market reaction. The technology giant posted second-quarter results that surpassed Wall Street’s forecasts for both revenue and profit. However, investors focused on a single area of weakness, sending the share price downward in a clear demonstration of how sensitive markets can be to minor disappointments within a tech company’s portfolio.

Financial Performance Exceeds Expectations, But Concerns Linger

On the surface, IBM’s quarterly report was impressive. Earnings per share climbed 15% to reach $2.80, comfortably exceeding the $2.65 analysts had projected. Total revenue saw an 8% increase, coming in at $16.98 billion. The market’s negative response, however, underscores that the details within these headline numbers often matter most.

A significant divergence emerged between the company’s business segments. The Infrastructure division was a clear standout, posting a robust 14% gain to reach $4.14 billion in revenue. In contrast, the Software unit generated $7.39 billion, a figure that narrowly missed analyst expectations. A deeper concern for investors was the segment’s adjusted growth rate, which decelerated to 8% from the 9% growth recorded in the previous quarter. As Jefferies analyst Brent Thill noted, the software narrative remains solid but is no longer an exclamation point for the company.

Explosive AI Growth Fails to Offset Broader Concerns

Counterbalancing the software slowdown, IBM’s artificial intelligence business is experiencing spectacular expansion. Chief Executive Officer Arvind Krishna announced that the generative AI segment has now grown to a portfolio worth over $7.5 billion. This represents a massive leap from the approximately $2 billion in business it held just one year ago, fueled by sustained demand for AI agents and the company’s open-source Granite series models.

Should investors sell immediately? Or is it worth buying IBM?

Despite this explosive growth, a key question remains for shareholders: is the AI boom sufficient to counterbalance emerging softness in the core software business? The market’s initial verdict appeared negative. Despite the overall strong earnings, IBM’s stock fell 8% following the report, a drop that pushed it through several key technical support levels.

Mixed Analyst Sentiment and a Confident Outlook

Wall Street analysts offered a divided perspective on the results. Some firms, like Wedbush, maintained a bullish “Outperform” rating with a $325 price target. Others, including Jefferies, opted for a more cautious “Neutral” stance. The average price target from UBS, JP Morgan, and Bank of America sits at $266.67, which still suggests a potential double-digit upside from current levels.

IBM’s own guidance reflected management’s confidence. The company raised its full-year forecast for free cash flow to more than $13.5 billion and reaffirmed its revenue growth expectation of at least 5%.

The central dilemma for investors is whether the remarkable ascent of IBM’s AI operations will be enough to permanently offset any minor weaknesses in software, or if the stock’s sell-off reveals deeper, fundamental doubts about the sustainability of the company’s ongoing transformation.

Ad

IBM Stock: Buy or Sell?! New IBM Analysis from February 7 delivers the answer:

The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

IBM: Buy or sell? Read more here...

Tags: IBM
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Next Post
iHeartMediaClass A Stock

iHeartMedia's Digital Growth Offsets Legacy Radio Challenges

j2 Global Stock

Ziff Davis Stock Surges on Strong Quarterly Performance

Parke Stock

Insider Sales at Parke: A Contrarian Signal or Personal Portfolio Management?

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com